SHANGHAI, Dec. 30, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scarring recently completed the first patient dosing in China, becoming the world’s first IL-11 targeting drug candidate to initiate clinical trials for pathological scarring.
This Phase II clinical trial (CTR20254857) aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring. The first patient was dosed at the Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. Previously, 9MW3811 had completed Phase I trials in healthy subjects in Australia and China, with results showing good safety profile and a half-life of more than one month.
Interleukin-11 (IL-11) is a cytokine that plays a critical role in chronic inflammation and fibrosis-related diseases, and is widely involved in the fibrosis process of multiple organs. Preclinical research shows that 9MW3811 has demonstrated significant efficacy in various models such as pulmonary fibrosis, and has shown potential application value in fibrosis-related diseases such as hypertrophic scar and abnormal endometrial bleeding. Especially in human-derived keloid animal models, 9MW3811 can effectively alleviate the skin fibrosis process and reduce the volume of established scars. Currently, there is a lack of effective therapeutic drugs for hypertrophic scars and keloids, indicating significant unmet clinical needs. 9MW3811 is expected to bring new treatment options to patients.
About Mabwell
Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from Ideas to Reality.” For more information, please visit www.mabwell.com/en.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.
Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.
The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.
View original content:https://www.prnewswire.com/news-releases/mabwell-announces-first-patient-dosed-in-phase-ii-trial-of-anti-il-11-antibody-for-pathological-scarring-302650129.html
SOURCE Mabwell
